Information de reference pour ce titreAccession Number: | 00003656-201006100-00010.
|
Author: | Bhalla, Shaifali a,*; Zhang, Zhong a; Patterson, Nicole b; Gulati, Anil a
|
Institution: | (a)Department of Pharmaceutical Sciences, Chicago College of Pharmacy, Midwestern University, Downers Grove, IL 60515, United States (b)College of Health Sciences, Midwestern University, Downers Grove, IL 60515, United States
|
Title: | |
Source: | European Journal of Pharmacology. 635(1):62-71, June 2010.
|
Abstract: | : We have previously shown the involvement of central endothelin (ET) mechanisms in morphine analgesia and tolerance. Here we investigated the interaction of centrally administered endothelin ETA receptor antagonist, BMS182874, with DAMGO ([mu] opioid receptor agonist), SNC80 ([delta] opioid receptor agonist), U50,488H ([kappa] opioid receptor agonist), and oxycodone ([mu] and [kappa] opioid receptor agonist) towards antinociception, tolerance to antinociception and body temperature. Antinociception was determined using tail-flick latency method. BMS182874 (50 [mu]g, i.c.v.) treatment alone did not produce analgesia or change in body temperature. However, BMS182874 significantly enhanced antinociception response of DAMGO (66.75%), SNC80 (62.40%), U50,488H (55.38%), and oxycodone (61.72%). Chronic treatment with DAMGO, SNC80, U50,488H or oxycodone, induced tolerance to antinociception. Treatment with BMS182874 restored antinociceptive effect in mice that were tolerant to DAMGO, SNC80, U50,488H as well as oxycodone. Antinociceptive response of DAMGO, SNC80, U50,488H, and oxycodone in tolerant mice treated with BMS182874 was significantly higher (44.55%, 37.48%, 43.02%, and 56.08%, respectively) compared to tolerant mice treated with vehicle. Body temperature decreased with DAMGO, SNC80, U50,488H, and oxycodone; tolerance did not develop to hypothermic effect and BMS182874 did not affect DAMGO, SNC80, U50,488H, or oxycodone induced changes in body temperature. Opioid-antagonist naloxone, completely blocked antinociceptive effect of DAMGO, SNC80, U50,488H or oxycodone and potentiation of antinociception by BMS182874. It is concluded that BMS182874 potentiated antinociception and restored antinociceptive effect in mice tolerant to [mu], [delta] and [kappa] selective, as well as a non-selective opioid receptor agonist. Therefore, endothelin ETA receptor antagonists could be useful in the restoration of antinociceptive effect during tolerance to opiates.
(C) 2010Elsevier, Inc.
|
Author Keywords: | Mu; Kappa; Delta; Opioid receptors; DAMGO; Oxycodone; SNC80; U50,488H; BMS182874; Antinociception; Tolerance; Endothelin.
|
References: | Aurilio, C., Pace, M.C., Pota, V., Sansone, P., Barbarisi, M., Grella, E., Passavanti, M.B., 2009. Opioids switching with transdermal systems in chronic cancer pain. Journal of Experimental & Clinical Cancer Research. 28, 61.
Baker, A.K., Meert, T.F., 2002. Functional effects of systemically administered agonists and antagonists of mu, delta, and kappa opioid receptor subtypes on body temperature in mice. The Journal of Pharmacology and Experimental Therapeutics. 302, 1253-1264.
Bhalla, S., Matwyshyn, G., Gulati, A., 2002. Potentiation of morphine analgesia by BQ123, an endothelin antagonist. Peptides. 23, 1837-1845.
Bhalla, S., Matwyshyn, G., Gulati, A., 2003. Endothelin receptor antagonists restore morphine analgesia in morphine tolerant rats. Peptides. 24, 553-561.
Bhalla, S., Matwyshyn, G., Gulati, A., 2005. Morphine tolerance does not develop in mice treated with endothelin-A receptor antagonists. Brain Research. 1064, 126-135.
Bhargava, H.N., Kumar, S., 1997. Effect of multiple injections of U-50, 488H, a kappa-opioid receptor agonist, on the activity of nitric oxide synthase in brain regions and spinal cord of mice. General Pharmacology. 29, 397-399.
Brandt, M.R., Furness, M.S., Rice, K.C., Fischer, B.D., Negus, S.S., 2001. Studies of tolerance and dependence with the delta-opioid agonist SNC80 in rhesus monkeys responding under a schedule of food presentation. The Journal of Pharmacology and Experimental Therapeutics. 299, 629-637.
Celver, J., Xu, M., Jin, W., Lowe, J., Chavkin, C., 2004. Distinct domains of the mu-opioid receptor control uncoupling and internalization. Molecular Pharmacology. 65, 528-537.
Christie, M.J., 2008. Cellular neuroadaptations to chronic opioids: tolerance, withdrawal and addiction. British Journal of Pharmacology. 154, 384-396.
Codd, E.E., Carson, J.R., Colburn, R.W., Stone, D.J., Van Besien, C.R., Zhang, S.P., Wade, P.R., Gallantine, E.L., Meert, T.F., Molino, L., Pullan, S., Razler, C.M., Dax, S.L., Flores, C.M., 2009. JNJ-20788560 [9-(8-azabicyclo[3.2.1]oct-3-ylidene)-9H-xanthene-3-carboxylic acid diethylamide], a selective delta opioid receptor agonist, is a potent and efficacious antihyperalgesic agent that does not produce respiratory depression, pharmacologic tolerance, or physical dependence. The Journal of Pharmacology and Experimental Therapeutics. 329, 241-251.
Cox, B.M., Crowder, A.T., 2004. Receptor domains regulating mu opioid receptor uncoupling and internalization: relevance to opioid tolerance. Molecular Pharmacology. 65, 492-495.
D'Amour, F.E., Smith, D.L., 1941. A method for determining loss of pain sensation. The Journal of Pharmacology and Experimental Therapeutics. 71, 74-79.
Dang, V.C., Williams, J.T., 2005. Morphine-induced mu-opioid receptor desensitization. Molecular Pharmacology. 68, 1127-1132.
Danielsson, I., Gasior, M., Stevenson, G.W., Folk, J.E., Rice, K.C., Negus, S.S., 2006. Electroencephalographic and convulsant effects of the delta opioid agonist SNC80 in rhesus monkeys. Pharmacology, Biochemistry, and Behavior. 85, 428-434.
DeHaven-Hudkins, D.L., Dolle, R.E., 2004. Peripherally restricted opioid agonists as novel analgesic agents. Current Pharmaceutical Design. 10, 743-757.
Do Carmo, G.P., Mello, N.K., Rice, K.C., Folk, J.E., Negus, S.S., 2006. Effects of the selective delta opioid agonist SNC80 on cocaine- and food-maintained responding in rhesus monkeys. European Journal of Pharmacology. 547, 92-100.
Eliav, E., Herzberg, U., Caudle, R.M., 1999. The kappa opioid agonist GR89, 696 blocks hyperalgesia and allodynia in rat models of peripheral neuritis and neuropathy. Pain. 79, 255-264.
Gallantine, E.L., Meert, T.F., 2005. A comparison of the antinociceptive and adverse effects of the mu-opioid agonist morphine and the delta-opioid agonist SNC80. Basic & Clinical Pharmacology & Toxicology. 97, 39-51.
Garzon, J., Rodriguez-Munoz, M., de la Torre-Madrid, E., Sanchez-Blazquez, P., 2005. Effector antagonism by the regulators of G protein signalling (RGS) proteins causes desensitization of mu-opioid receptors in the CNS. Psychopharmacology. 180, 1-11.
Gulati, A., Rebello, S., Roy, S., Saxena, P.R., 1995. Cardiovascular effects of centrally administered endothelin-1 in rats. Journal of Cardiovascular Pharmacology. 26, S244-S246.
Haley, T.J., McCormick, W.G., 1957. Pharmacological effects produced by intracerebral injections of drugs in the conscious mouse. British Journal of Pharmacology and Chemotherapy. 12, 12-15.
Handler, C.M., Geller, E.B., Adler, M.W., 1992. Effect of mu-, kappa-, and delta-selective opioid agonists on thermoregulation in the rat. Pharmacology, Biochemistry, and Behavior. 43, 1209-1216.
Helm, S., Trescot, A.M., Colson, J., Sehgal, N., Silverman, S., 2008. Opioid antagonists, partial agonists, and agonists/antagonists: the role of office-based detoxification. Pain Physician Journal. 11, 225-235.
Jarvis, M.F., Wessale, J.L., Zhu, C.Z., Lynch, J.J., Dayton, B.D., Calzadilla, S.V., Padley, R.J., Opgenorth, T.J., Kowaluk, E.A., 2000. ABT-627, an endothelin ET(A) receptor-selective antagonist, attenuates tactile allodynia in a diabetic rat model of neuropathic pain. European Journal of Pharmacology. 388, 29-35.
Jiang, Q., Mosberg, H.I., Porreca, F., 1990. Modulation of the analgesic efficacy and potency of morphine by [D-Pen2, D-Pen5]enkephalin in mice. Progress in Clinical Biological Research. 328, 449-452.
Koch, T., Hollt, V., 2008. Role of receptor internalization in opioid tolerance and dependence. Pharmacology & Therapeutics. 117, 199-206.
Law, P.Y., Loh, H.H., 1999. Regulation of opioid receptor activities. The Journal of Pharmacology and Experimental Therapeutics. 289, 607-624.
Le Bourdonnec, B., Windh, R.T., Ajello, C.W., Leister, L.K., Gu, M., Chu, G.H., Tuthill, P.A., Barker, W.M., Koblish, M., Wiant, D.D., Graczyk, T.M., Belanger, S., Cassel, J.A., Feschenko, M.S., Brogdon, B.L., Smith, S.A., Christ, D.D., Derelanko, M.J., Kutz, S., Little, P.J., DeHaven, R.N., DeHaven-Hudkins, D.L., Dolle, R.E., 2008. Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N, N-diethyl-4-(5-hydroxyspiro[chromene-2, 4'-piperidine]-4-yl)benzamide (ADL5859). Journal of Medicinal Chemistry. 51, 5893-5896.
Le Bourdonnec, B., Windh, R.T., Leister, L.K., Zhou, Q.J., Ajello, C.W., Gu, M., Chu, G.H., Tuthill, P.A., Barker, W.M., Koblish, M., Wiant, D.D., Graczyk, T.M., Belanger, S., Cassel, J.A., Feschenko, M.S., Brogdon, B.L., Smith, S.A., Derelanko, M.J., Kutz, S., Little, P.J., DeHaven, R.N., DeHaven-Hudkins, D.L., Dolle, R.E., 2009. Spirocyclic delta opioid receptor agonists for the treatment of pain: discovery of N, N-diethyl-3-hydroxy-4-(spiro[chromene-2, 4'-piperidine]-4-yl) benzamide (ADL5747). Journal of Medicinal Chemistry. 52, 5685-5702.
MacCumber, M.W., Ross, C.A., Snyder, S.H., 1990. Endothelin in brain: receptors, mitogenesis, and biosynthesis in glial cells. Proceedings of the National Academy of Sciences of the United States of America. 87, 2359-2363.
Mansour, A., Fox, C.A., Burke, S., Meng, F., Thompson, R.C., Akil, H., Watson, S.J., 1994. Mu, delta, and kappa opioid receptor mRNA expression in the rat CNS: an in situ hybridization study. The Journal of Comparative Neurology. 350, 412-438.
Mansour, A., Hoversten, M.T., Taylor, L.P., Watson, S.J., Akil, H., 1995. The cloned mu, delta and kappa receptors and their endogenous ligands: evidence for two opioid peptide recognition cores. Brain Research. 700, 89-98.
Mattia, A., Vanderah, T., Mosberg, H.I., Porreca, F., 1991. Lack of antinociceptive cross-tolerance between [D-Pen2, D-Pen5]enkephalin and [D-Ala2]deltorphin II in mice: evidence for delta receptor subtypes. The Journal of Pharmacology and Experimental Therapeutics. 258, 583-587.
Matwyshyn, G.A., Bhalla, S., Gulati, A., 2006. Endothelin ETA receptor blockade potentiates morphine analgesia but does not affect gastrointestinal transit in mice. European Journal of Pharmacology. 543, 48-53.
Meng, F., Xie, G.X., Thompson, R.C., Mansour, A., Goldstein, A., Watson, S.J., Akil, H., 1993. Cloning and pharmacological characterization of a rat kappa opioid receptor. Proceedings of the National Academy of Sciences of the United States of America. 90, 9954-9958.
Monory, K., Greiner, E., Sartania, N., Sallai, L., Pouille, Y., Schmidhammer, H., Hanoune, J., Borsodi, A., 1999. Opioid binding profiles of new hydrazone, oxime, carbazone and semicarbazone derivatives of 14-alkoxymorphinans. Life Sciences. 64, 2011-2020.
Perrine, S.A., Hoshaw, B.A., Unterwald, E.M., 2006. Delta opioid receptor ligands modulate anxiety-like behaviors in the rat. British Journal of Pharmacology. 147, 864-872.
Poyhia, R., Kalso, E.A., 1992. Antinociceptive effects and central nervous system depression caused by oxycodone and morphine in rats. Pharmacology and Toxicology. 70, 125-130.
Quock, R.M., Hosohata, Y., Knapp, R.J., Burkey, T.H., Hosohata, K., Zhang, X., Rice, K.C., Nagase, H., Hruby, V.J., Porreca, F., Roeske, W.R., Yamamura, H.I., 1997. Relative efficacies of delta-opioid receptor agonists at the cloned human delta-opioid receptor. European Journal of Pharmacology. 326, 101-104.
Rebello, S., Roy, S., Saxena, P.R., Gulati, A., 1995. Systemic hemodynamic and regional circulatory effects of centrally administered endothelin-1 are mediated through ETA receptors. Brain Research. 676, 141-150.
Riviere, P.J., 2004. Peripheral kappa-opioid agonists for visceral pain. British Journal of Pharmacology. 141, 1331-1334.
Sakurai, T., Yanagisawa, M., Takuwa, Y., Miyazaki, H., Kimura, S., Goto, K., Masaki, T., 1990. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature. 348, 732-735.
Slatkin, N.E., 2009. Opioid switching and rotation in primary care: implementation and clinical utility. Current Medical Research and Opinion. 25, 2133-2150.
Toda, N., Kishioka, S., Hatano, Y., Toda, H., 2009. Modulation of opioid actions by nitric oxide signaling. Anesthesiology. 110, 166-181.
Ueda, H., Ueda, M., 2009. Mechanisms underlying morphine analgesic tolerance and dependence. Frontiers in Bioscience. 14, 5260-5272.
Van Ree, J.M., Gerritis, M.A.F.M., Vanderschuren, L.J.M.J., 1999. Opioids, reward and addiction: an ancounter of biology, psychology, and medicine. Pharmacological Reviews. 51, 342-396.
Vonvoigtlander, P.F., Lahti, R.A., Ludens, J.H., 1983. U-50, 488: a selective and structurally novel non-Mu (kappa) opioid agonist. The Journal of Pharmacology and Experimental Therapeutics. 224, 7-12.
Wang, X., Xu, H., Rothman, R.B., 2004. Intracerebroventricular administration of anti-endothelin-1 IgG selectively upregulates endothelin-A and kappa opioid receptors. Neuroscience. 129, 751-756.
Wang, X., Xu, H., Rothman, R.B., 2006. Regulation of the rat brain endothelin system by endogenous beta-endorphin. Peptides. 27, 769-774.
Williams, J.T., Christie, M.J., Manzoni, O., 2001. Cellular and synaptic adaptations mediating opioid dependence. Physiological Reviews. 81, 299-343.
Yamamoto, T., Shono, K., Tanabe, S., 2006. Buprenorphine activates mu and opioid receptor like-1 receptors simultaneously, but the analgesic effect is mainly mediated by mu receptor activation in the rat formalin test. The Journal of Pharmacology and Experimental Therapeutics. 318, 206-213.
Yanagisawa, M., Kurihara, H., Kimura, S., Goto, K., Masaki, T., 1988. A novel peptide vasoconstrictor, endothelin, is produced by vascular endothelium and modulates smooth muscle Ca2+ channels. Journal of Hypertension Supplement. 6, S188-S191.
|
Language: | English.
|
Document Type: | Neuropharmacology and Analgesia.
|
Journal Subset: | Pharmacology.
|
ISSN: | 0014-2999
|
NLM Journal Code: | en6, 1254354
|
DOI Number: | https://dx.doi.org/10.1016/j.ejp...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|